Profound Medical (NASDAQ:PROF) Shares Down 1.6% – Here’s What Happened

Posted by Brenda Bartman on Aug 30th, 2026

Shares of Profound Medical (NASDAQ:PROF – Get Free Report) were down 1.6% during mid-day trading on Friday . The company traded as low as $6.82 and last traded at $6.85. Approximately 18,183 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 117,764 shares. The stock had previously closed at $6.96.

Wall Street Analysts Forecast Growth

PROF has been the subject of a number of research reports. Weiss Ratings cut Profound Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 12th. Raymond James Financial raised Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 target price on the stock in a research report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Get Our Latest Stock Report on Profound Medical

Profound Medical Price Performance

The firm has a market capitalization of $248.93 million, a P/E ratio of -6.99 and a beta of 0.73. The company’s 50-day simple moving average is $7.04 and its two-hundred day simple moving average is $6.74.

Profound Medical (NASDAQ:PROF – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Profound Medical had a negative return on equity of 63.03% and a negative net margin of 171.57%.The business had revenue of $2.48 million for the quarter, compared to analysts’ expectations of $4.75 million. Analysts predict that Profound Medical will post -0.81 earnings per share for the current year.

Hedge Funds Weigh In On Profound Medical

Several institutional investors and hedge funds have recently bought and sold shares of PROF. Penbrook Management LLC purchased a new stake in Profound Medical in the first quarter worth about $80,000. Goldman Sachs Group Inc. raised its stake in shares of Profound Medical by 56.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,727 shares of the company’s stock worth $147,000 after buying an additional 6,787 shares during the period. Concurrent Investment Advisors LLC purchased a new position in shares of Profound Medical during the 2nd quarter valued at about $144,000. Corsair Capital Management L.P. purchased a new position in shares of Profound Medical during the 4th quarter valued at about $208,000. Finally, Millennium Management LLC bought a new position in shares of Profound Medical during the 4th quarter valued at approximately $211,000. 47.86% of the stock is currently owned by hedge funds and other institutional investors.

Profound Medical Company Profile

(Get Free Report)

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.